Compare NKLR & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKLR | ZURA |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | Italy | United States |
| Employees | N/A | 30 |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.7M | 435.0M |
| IPO Year | N/A | N/A |
| Metric | NKLR | ZURA |
|---|---|---|
| Price | $4.03 | $6.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $15.00 | $11.78 |
| AVG Volume (30 Days) | 385.1K | ★ 482.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.73 | $0.99 |
| 52 Week High | $12.43 | $7.19 |
| Indicator | NKLR | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 60.94 |
| Support Level | $3.90 | $5.62 |
| Resistance Level | $5.25 | N/A |
| Average True Range (ATR) | 0.36 | 0.50 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 3.97 | 80.14 |
Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.